Abstract
For patients with COPD, inhalation is the preferred route of administration of respiratory drugs for both maintenance and acute treatment. Numerous inhaler types and devices have been developed, each with their own particularities, advantages and disadvantages. Nevertheless, published COPD management guidelines pay little attention to the optimal choice of inhaler devices for COPD patients. Although efficacy and safety are the primary factors determining the choice of an inhaler device, randomised controlled trials (RCTs) directly comparing the efficacy and safety of different inhalers in COPD patients are scarce. Systematic reviews on this subject failed to find significant differences between devices for any of the clinical outcomes studied. When selecting a device for the delivery of inhaled drugs in ‘real life’ patients with COPD, other factors should be considered. These include availability and affordability of the inhaled drugs and inhaler devices, the uniformity of inhaler devices when several drugs are to be inhaled, the ability of patients to handle correctly the selected device — in particular taking into account the advanced age of the average COPD patient, and finally the patient's preference. The prescribing clinician's task is to provide comprehensive instructions for correct handling of the device and to review regularly the patient's inhalation technique.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Competing interests
Conflicts of interest for all ADMIT members are listed at the end of the first paper in this series — see Dekhuijzen et al. Prim Care Resp J 2007;16(6):341–8.
Rights and permissions
About this article
Cite this article
Vincken, W., Dekhuijzen, R., Barnes, P. et al. The ADMIT series — Issues in Inhalation Therapy. 4) How to choose inhaler devices for the treatment of COPD. Prim Care Respir J 19, 10–20 (2010). https://doi.org/10.4104/pcrj.2009.00062
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4104/pcrj.2009.00062
This article is cited by
-
Incorporating the Environmental Impact into a Budget Impact Analysis: The Example of Adopting RESPIMAT® Re-usable Inhaler
Applied Health Economics and Health Policy (2020)
-
CFPD simulation of magnetic drug delivery to a human lung using an SAW nebulizer
Biomechanics and Modeling in Mechanobiology (2019)
-
A Budget Impact Model to Estimate the Environmental Impact of Adopting RESPIMAT® Re-usable in the Nordics and Benelux
Advances in Therapy (2019)
-
Adherence to inhaled therapy and its impact on chronic obstructive pulmonary disease (COPD)
BMC Pulmonary Medicine (2018)
-
Patient preferences for dry powder inhaler attributes in asthma and chronic obstructive pulmonary disease in France: a discrete choice experiment
BMC Pulmonary Medicine (2017)